1. Home
  2. News & Press
  3. Assurex Health Announces Key Leadership Hires To Support Continued Growth

Assurex Health Announces Key Leadership Hires To Support Continued Growth

Assurex Health Announces Key Leadership Hires To Support Continued Growth

Eckert, Findley to Guide Legal, People Teams; Verratti to Focus on GeneSight® Adoption

Mason, Ohio – March 15, 2016 – Assurex Health, Inc., an informatics-based precision medicine company known primarily for its GeneSight test, a clinically proven test to help enhance medication selection for neuropsychiatric conditions, has announced appointments to three key leadership roles.

Inger H. Eckert has joined the company as General Counsel, Mary Sue Findley has been named Chief People Officer, and Mark Verratti has taken the role of Chief Sales and Business Development Officer, according to Assurex Health President and CEO Virginia C. Drosos.

“Assurex Health continues to gain industry-leading clinical adoption, coverage and reimbursement for our GeneSight test,” Drosos said. “With nearly 440 employees, an expanding intellectual property portfolio, and over 16,000 healthcare providers having ordered GeneSight, Inger, Mary Sue, and Mark will be integral members of our leadership team.”

“Each of them brings relevant experience, a track record of results and passion for our company’s vision for helping people get on the road to mental wellness,” Drosos added.

Innovation-Centered Eckert Named as General Counsel

With over 20 years’ experience at Fortune 500 companies, Inger H. Eckert is a business-minded corporate attorney with broad experience in leading large corporate legal departments and fostering innovation for competitive advantage. As Senior Vice President and General Counsel at Assurex Health, Inger will provide strategic guidance on corporate matters, develop legal strategies that provide competitive advantages, and shape policies on the company’s continued commitment to meet all regulatory and compliance standards.

Before joining Assurex Health, Eckert served as Chief Counsel, Global Intellectual Property and General Counsel for the Corporate Technology division of International Paper. She also held roles as Director, Global Intellectual Property, at Owens Corning and as an Intellectual Property Attorney at Ford Motor Company. Inger holds her J.D., cum laude, from the University of Dayton, and a B.S. in Electrical Engineering Technology from The Pennsylvania State University.

Findley Has Guided Fast-Growing, People-Focused Organizations

Mary Sue Findley has more than 25 years of experience leading human resources teams – from highly entrepreneurial organizations to large corporations. As Senior Vice President and Chief People Officer at Assurex Health, Findley will drive organizational development to optimize the company’s human resources.

Before joining Assurex Health, Findley served as Senior Vice President of Human Resources at dunnhumby, where she helped drive the company’s rapid growth and the recent spin-off of 84.51°. She’s also held positions at Fifth Third Bancorp and Eddie Bauer Stores. Mary Sue earned her bachelor’s in Business Administration from The University of Dayton and her master’s in Labor and Human Resources from The Ohio State University.

Verratti to Focus on Broad Adoption of GeneSight

Mark Verratti has an excellent track record of driving commercial success and strong revenue growth in the healthcare industry. Mark has over 20 years of extensive experience building and leading successful pharma and medical devices sales teams, both in the US and internationally. He will lead Assurex Health’s domestic and international sales efforts and will also help broaden the adoption of the company’s GeneSight products in the US through distribution partnerships reaching new clinician specialties as well as institutions like hospitals, colleges and universities.

“As the leader in neuropsychiatric pharmacogenomics, we have significant opportunity to leverage our first mover advantage to drive growth,” Drosos said. “Mark will be leading our sales team while working closely with our science and informatics leaders to identify new products, technologies and partnerships to broaden our value-add to more healthcare providers.”

Verratti was previously with Houston, Texas-based Cyberonics, Inc., a global medical device company engaged in the design, development, sales and marketing of medical devices for the treatment of neurological disorders. He started his career with Forest Pharmaceuticals. Verratti has a bachelor’s degree from Penn State University.

About Assurex Health
Assurex Health is an informatics-based precision medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions. We help people achieve mental wellness with advanced CPGx, a proprietary combinatorial pharmacogenomics technology providing individualized treatment support for neuropsychiatric conditions.

Assurex Health is the leader in neuropsychiatric combinatorial pharmacogenomics. It was founded in 2006 with licensed, patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center, who continue to be research collaborators. Assurex Health is the only company in the category with multiple peer-reviewed, published studies that demonstrate the clinical validity and clinical utility of its technology, including its substantial healthcare cost savings benefit. The company has grown every quarter, and also has expanded internationally through a partnership with Canada’s Centre for Addiction and Mental Health (CAMH).

About GeneSight
GeneSight helps healthcare providers make more precise treatment decisions based on how a patient’s unique genetic makeup affects their individual response to 55 FDA-approved medications for depression, anxiety, posttraumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other mental health conditions. GeneSight is the only neuropsychiatric combinatorial pharmacogenomic test validated in multiple, peer-reviewed, published clinical studies. Powered by CPGx Technology, a proprietary combinatorial pharmacogenomics technology, the GeneSight test measures multiple genomic variants for each patient and weights them together – rather than one at a time – to provide comprehensive genetically-driven information for each medication for each patient in an actionable, easy-to-interpret report. Many commercial and government insurance plans, including Medicare and the U.S. Department of Veterans Affairs, reimburse all or part of the cost of GeneSight. Assurex Health also offers financial assistance programs for patients who qualify.